Emergent Biosolutions
EBS
208 hedge funds and large institutions have $1.17B invested in Emergent Biosolutions in 2016 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 76 increasing their positions, 67 reducing their positions, and 28 closing their positions.
64% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $804K
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
13% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 67
2% more funds holding
Funds holding: 203 → 208 (+5)
2% more capital invested
Capital invested by funds: $1.15B → $1.17B (+$24.6M)
2.25% less ownership
Funds ownership: 90.5% → 88.25% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$12M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.2M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$9.05M |
| 4 |
AAM
Aberdeen Asset Management
Aberdeen,
United Kingdom
|
+$7.57M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
+$5.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$23.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.3M |
| 3 |
Renaissance Technologies
New York
|
-$8.83M |
| 4 |
Goldman Sachs
New York
|
-$8.42M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.88M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
226
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$279K | -8,859 | Closed |
|
|
DC
227
Deere & Company
Moline,
Illinois
| – | -$226K | -7,173 | Closed |
|
228
Los Angeles Capital Management
Los Angeles,
California
| – | -$207K | -6,573 | Closed |
|
|
PMAM
229
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$76K | -2,400 | Closed |
|
230
Simplex Trading
Chicago,
Illinois
| – | -$34.5K | -1,151 | -99% |
|
|
MWP
231
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
| – | -$16K | -500 | Closed |
|
232
Bessemer Group
Woodbridge,
New Jersey
| – | -$13K | -412 | Closed |
|
|
CG
233
Cutler Group
San Francisco,
California
| – | -$8.99K | -300 | Closed |
|
|
AG
234
Advisor Group
Phoenix,
Arizona
| – | -$4K | -139 | Closed |
|
|
ACH
235
ArrowMark Colorado Holdings
Denver,
Colorado
| – | -$1K | -33 | Closed |
|
EBS Hedge Fund Activity: Q4 2016 in Review
208 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2016, worth a combined $1.17B — up 2.1% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new EBS positions and 28 closed out — a net gain of 9 holders — while 76 added to existing stakes and 67 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $12M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $23.3M sold.
- 208 institutional investors held Emergent Biosolutions (EBS) as of Q4 2016, up from 203 in Q3 2016.
- Funds reported $1.17B of Emergent Biosolutions stock for Q4 2016, up 2.1% quarter-over-quarter.
- 37 funds opened new Emergent Biosolutions positions in Q4 2016 and 28 closed out, a net change of +9 holders.
- The largest Emergent Biosolutions buyer in Q4 2016 was Royal Bank of Canada, an estimated $12M added.
- The largest Emergent Biosolutions seller in Q4 2016 was Arrowstreet Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2016.